Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 14/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 14/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 14/20 | 1.00 |
| ▸ | FLT1 | P17948 | 13/20 | 1.00 |
| ▸ | FLT4 | P35916 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26928578 | 1.00 | FGFR1 (1.00) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL27218112 | 0.91 | FGFR1 (0.82) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL24490292 | 0.84 | FGFR1 (1.00) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL16868903 | 0.83 | FGFR1 (1.00) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL14040752 | 0.80 | FGFR1 (1.00) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL26928630 | 0.78 | FGFR1 (1.00) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL19601461 | 0.78 | FGFR1 (0.88) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL22532398 | 0.77 | FGFR1 (0.87) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL22532348 | 0.77 | FGFR1 (0.87) | FGFR1KDRFGFR2FGFR4FGFR3 | |
| SCHEMBL29391039 | 0.77 | FGFR1 (0.87) | FGFR1KDRFGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240271-A1 | USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY | FOUNTAIN THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023240271-A1 | USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY | FOUNTAIN THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |